Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: Opening of a new era

European Journal of Endocrinology

Volumn 168, Issue 1, 2013, Pages

  Catena, Cristiana ^a   Colussi, GianLuca ^a   Sechi, Leonardo A ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; EPLERENONE; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADRENALECTOMY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; COMPARATIVE EFFECTIVENESS; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MICROALBUMINURIA; NOTE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENOVASCULAR DISEASE; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

FEMALE; HUMANS; HYPERALDOSTERONISM; KIDNEY; MALE; SPIRONOLACTONE;

EID: 84871980783     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0899     Document Type: Note

References (32)

1. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C & Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. Journal of Hypertension 2003 21 2149-2157. (doi:10.1097/00004872- 200311000-00025)
2. Young WF. Primary aldosteronism: renaissance of a syndrome. Clinical Endocrinology 2007 66 607-618. (doi:10.1111/j.1365-2265.2007.02775.x)
3. Conn JW, Knopf RF & Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. American Journal of Surgery 1964 107 159-172. (doi:10.1016/0002-9610(64)90252-1)
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME & Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 1243-1248. (doi:10.1016/j.jacc.2005.01.015)
5. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R & Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Archives of Internal Medicine 2008 168 80-85. (doi:10.1001/ archinternmed.2007.33)
6. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney International 2004 66 1-9. (doi:10.1111/j.1523-1755.2004.00701.x)
7. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P & Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends in Endocrinology and Metabolism 2008 19 88-90. (doi:10.1016/j.tem.2008. 01.006)
8. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr & Montori VM. Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10.1210/jc.2008-0104)
9. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P & Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007 50 911-918. (doi:10.1161/HYPERTENSIONAHA.107.095448)
10. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL & Catena C. Long-term renal outcomes in patients with primary aldosteronism. Journal of the American Medical Association 2006 295 2638-2645. (doi:10.1001/jama.295.22.2638)
11. Sechi LA, Colussi G, Di Fabio A & Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. American Journal of Hypertension 2010 23 1253-1260. (doi:10.1038/ajh.2010.169)
12. Catena C, Colussi G, Di Fabio A, Valeri M, Marzano L, Uzzau A & Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Hormone and Metabolic Research 2010 42 440-4455. (doi:10.1055/s-0029-1246185)
13. Rossi GP, Pessina AC & Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. Journal of Hypertension 2008 26 613-621. (doi:10.1097/HJH.0b013e3282f4b3e6)
14. Kaplan NM. Primary aldosteronism: an update on screening, diagnosis and treatment. Journal of Hypertension 2008 26 1708-1709. (doi:10.1097/HJH. 0b013e328302ee10)
15. Kaplan NM. Primary aldosteronism: evidence against a second epidemic. Journal of Hypertension 2012 30 1899-1902. (doi:10.1097/HJH.0b013e3283559a03)
16. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K & Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008 371 1921-1926. (doi:10.1016/S0140-6736(08)60834-X)
17. Funder JW. Primary aldosteronism: are we missing the wood for the trees. Hormone and Metabolic Research 2012 44 251-253. (doi:10.1055/s-0031-1301281)
18. Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, Beuschlein F, Willenberg HS, Rump LC, Allolio B et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. European Journal of Endocrinology 2012.
19. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T & Kimura G. Cardiovascular complications in patients with primary aldosteronism. American Journal of Kidney Diseases 1999 33 261-266. (doi:10.1016/S0272-6386(99) 70298-2)
20. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R & Sechi LA. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clinical Journal of the American Society of Nephrology 2007 2 722-731. (doi:10.2215/CJN.00050107)
21. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2009 94 869-875. (doi:10.1210/jc.2008- 1851)
22. Danforth DN Jr, Orlando MM, Bartter FC & Javadpour N. Renal changes in primary aldosteronism. Journal of Urology 1977 117 140-144. (Pubitemid 8047826)
23. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006 48 232-238. (doi:10.1161/01.HYP.0000230444.01215.6a)
24. Ribstein J, Du Cailar G, Fesler P & Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. Journal of the American Society of Nephrology 2005 16 1320-1325. (doi:10.1681/ASN.2004100878)
25. Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, Chu TS, Chang HW, Lin CY, Tsai CT et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. Journal of Hypertension 2011 29 1778-1786. (doi:10.1097/HJH.0b013e3283495cbb)
26. Kuo CC, Wu VC, Tsai CW & Wu KD. Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis. Journal of Renin-Angiotensin-Aldosterone System 2011 12 213-222.
27. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A & Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. Journal of Clinical Endocrinology and Metabolism 2009 94 1191-1197. (doi:10.1210/jc.2008- 2245)
28. Sechi LA & Catena C. The dual role of the kidney in primary aldosteronism: key determinant in rescue from volume expansion and persistence of hypertension. American Journal of Kidney Diseases 2009 54 594-597. (doi:10.1053/j.ajkd.2009.08.004)
29. Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, Ho YL, Lin WC, Wang SM, Huang KH et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. American Journal of Kidney Diseases 2009 54 665-673. (doi:10.1053/j.ajkd.2009.06.014)
30. Colussi GL, Catena C & Sechi LA. Spironolactone, eplerenone, and the new aldosterone blockers in endocrine and primary hypertension. Journal of Hypertension 2012. In press.
31. Ahmed AH, Gordon RD, Sukor N, Pimenta E & Stowasser M. Quality of life in patients with bilateral aldosteronism before and during treatment with spironolactone/amiloride, including comparison with our previously published results in those with unilateral disease treated surgically. Journal of Clinical Endocrinology and Metabolism 2011 96 2904-2911. (doi:10.1210/jc.2011-0138)
32. Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM & MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension 2011 29 980-990. (doi:10.1097/HJH.0b013e3283455ca5)